(BMRN) Biomarin Pharmaceutical - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013

Stock:

Total Rating 30

Risk 85

Buy Signal -1.24

Biotechnology +5.7
Biotechnology +5.6

Market Cap: 12,184m
Avg Trading Vol: 112M USD

ATR: 2.97%
Peers RS (IBD): 22.50

Risk 5d forecast
Volatility	31.4%
Relative Tail Risk	-11.0%

Reward TTM
Sharpe Ratio	-0.17
Alpha	-16.72

Character TTM
Beta	0.462
Beta Downside	1.479

Drawdowns 3y
Max DD	50.15%
CAGR/Max DD	-0.31

EPS (Earnings per Share)

EPS CAGR: -30.01%
EPS Trend: 49.4%

Last SUE: -2.06
Qual. Beats: 0

Revenue

Rev. CAGR: -66.37%
Rev. Trend: -39.9%

Last SUE: -4.00
Qual. Beats: 0

Description: BMRN Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 182.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 6.53 > 1.0
NWC/Revenue: -10.6k% < 20% (prev 85.04%; Δ -10.7k% < -1%)
CFO/TA 0.12 > 3% & CFO 914.0m > Net Income 182.5m
Net Debt (-645.9m) to EBITDA (200.8m): -3.22 < 3
Current Ratio: 4.83 > 1.5 & < 3
Outstanding Shares: last quarter (191.6m) vs 12m ago -2.79% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: -0.40% > 50% (prev 40.18%; Δ -40.58% > 0%)
Interest Coverage Ratio: -97.8k > 6 (EBITDA TTM 200.8m / Interest Expense TTM -2000 )

Altman Z'' 3.01

A: 0.40 (Total Current Assets 3.85b - Total Current Liabilities 798.4m) / Total Assets 7.61b
B: 0.03 (Retained Earnings 200.8m / Total Assets 7.61b)
C: 0.03 (EBIT TTM 195.6m / Avg Total Assets 7.23b)
D: 0.11 (Book Value of Equity 167.0m / Total Liabilities 1.56b)
Altman-Z'' Score: 3.01 = A

Beneish M

DSRI: none (Receivables 790.3m/777.5m, Revenue -28.8m/2.75b)
GMI: 1.00 (fallback, negative margins)
AQI: 0.89 (AQ_t 0.36 / AQ_t-1 0.40)
SGI: none (Revenue -28.8m / 2.75b)
TATA: -0.10 (NI 182.5m - CFO 914.0m) / TA 7.61b)
Beneish M-Score: cannot calculate (missing components)

What is the price of BMRN shares?

As of February 24, 2026, the stock is trading at USD 62.92 with a total of 4,740,937 shares traded.
Over the past week, the price has changed by +4.95%, over one month by +11.94%, over three months by +13.37% and over the past year by -8.82%.

Is BMRN a buy, sell or hold?

Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.

StrongBuy: 16
Buy: 7
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the BMRN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	88.9	41.2%
Analysts Target Price	88.9	41.2%

BMRN Fundamental Data Overview February 21, 2026

P/E Trailing = 23.5762
P/E Forward = 11.4679
P/S = 3.9379
P/B = 1.899
P/EG = 0.4606
Revenue TTM = -28.8m USD
EBIT TTM = 195.6m USD
EBITDA TTM = 200.8m USD
Long Term Debt = 596.7m USD (from longTermDebt, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 604.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -645.9m USD (from netDebt column, last quarter)
Enterprise Value = 11.31b USD (12.18b + Debt 604.2m - CCE 1.48b)
Interest Coverage Ratio = -97.8k (Ebit TTM 195.6m / Interest Expense TTM -2000 )
EV/FCF = 13.60x (Enterprise Value 11.31b / FCF TTM 831.4m)
FCF Yield = 7.35% (FCF TTM 831.4m / Enterprise Value 11.31b)
WARNING: Negative Revenue TTM = -28.8m
FCF Margin = -2885 % (FCF TTM 831.4m / Revenue TTM -28.8m)
WARNING: Negative Revenue TTM = -28.8m
Net Margin = -633.1% (Net Income TTM 182.5m / Revenue TTM -28.8m)
WARNING: Negative Revenue TTM = -28.8m
Gross Margin = unknown ((Revenue TTM -28.8m - Cost of Revenue TTM -3.95m) / Revenue TTM)
Tobins Q-Ratio = 1.49 (Enterprise Value 11.31b / Total Assets 7.61b)
Interest Expense / Debt = -1.34% (Interest Expense -8.12m / Debt 604.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 154.6m (EBIT 195.6m * (1 - 21.00%))
Current Ratio = 4.83 (Total Current Assets 3.85b / Total Current Liabilities 798.4m)
Debt / Equity = 0.10 (Debt 604.2m / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = -3.22 (Net Debt -645.9m / EBITDA 200.8m)
Debt / FCF = -0.78 (Net Debt -645.9m / FCF TTM 831.4m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.52% (Net Income 182.5m / Total Assets 7.61b)
RoE = 3.10% (Net Income TTM 182.5m / Total Stockholder Equity 5.88b)
RoCE = 3.02% (EBIT 195.6m / Capital Employed (Equity 5.88b + L.T.Debt 596.7m))
RoIC = 2.39% (NOPAT 154.6m / Invested Capital 6.48b)
WACC = 7.21% (E(12.18b)/V(12.79b) * Re(7.62%) + D(604.2m)/V(12.79b) * Rd(-1.34%) * (1-Tc(0.21)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.05%
[DCF Debug] Terminal Value 83.88% ; FCFF base≈619.2m ; Y1≈763.8m ; Y5≈1.30b
Fair Price DCF = 139.4 (EV 26.14b - Net Debt -645.9m = Equity 26.79b / Shares 192.1m; r=7.21% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 49.37 | EPS CAGR: -30.01% | SUE: -2.06 | # QB: 0
Revenue Correlation: -39.95 | Revenue CAGR: -66.37% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.28 | Chg30d=-0.030 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=5.26 | Chg30d=+0.011 | Revisions Net=+0 | Growth EPS=+60.7% | Growth Revenue=+6.9%

Additional Sources for BMRN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle